Barr launches generic fluoxetine 20 mg capsule Aug. 2 at $2.67 average wholesale price per capsule, a 10% discount to Lilly's Prozac. The launch follows entry of a final mandate in Prozac patent litigation in Indianapolis district court on July 27. Barr, Par and Geneva will have 180 days of Waxman/Hatch exclusivity on different fluoxetine formulations. Geneva's 10 mg capsule will have an AWP of $2.60; Par's fluoxetine formulations will launch with AWPs per pill of $2.60 (10 mg tablet), $2.67 (20 mg tablet) and $5.34 (40 mg capsule). Lilly's Prozac has a 24.3% share of the serotonin reuptake inhibitor market as of Aug. 3, according to data on the ArcLight "Rxeal Time" database. GSK's Paxil and Pfizer's Zoloft have a 27.2% and 30.0% share of this market, respectively
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
Advanz Pharma would have had to show that the European Commission’s decision to revoke Ocaliva’s conditional marketing approval risked causing serious and irreparable harm, according to lawyers from Van Bael & Bellis.
We are conducting a survey to better understand our subscribers’ content and delivery needs. If there are any changes you’d like to see in coverage topics, article format, or the method in which you access the Pink Sheet – or if you love it how it is – now is the time to have your voice heard.
The US FDA says its release of complete response letters for products subsequently approved by the agency is just a first step toward releasing rejection letters when they are issued, assuming legal issues can be resolved.
The FDA's recent announcement of plans to expand unannounced inspections at ex-US facilities should put firms on advance notice that their next foreign facility inspection may not be preannounced, Ivy Sweeney, acting head of the agency's drug inspections office said.
New US FDA drugs center director George Tidmarsh’s data-centric comments at a Reagan-Udall Foundation meeting on unapproved fluoride products could suggest patients’ and caregivers’ experiences will carry less weight in benefit-risk decisions under his leadership.